AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16276320 — intervention group
Group type: COMPARATOR
Intervention: Overnight corneal reshaping (OCR), CRT lenses by Paragon, worn only while sleeping.
Number of subjects: 81
Study 16276320 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference after both phases of the study.
Number of subjects: 81
Study 12107720 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion (1 mU/kg per min for 60 min) during adenosine infusion (140 microg/kg per min i.v.)
Number of subjects: 19
Study 12107720 — intervention group
Group type: COMPARATOR
Intervention: Adenosine infusion (140 microg/kg per min i.v.) without insulin
Number of subjects: 19
Study 12107720 — intervention group
Group type: COMPARATOR
Intervention: Normoglycaemia (plasma glucose 6 mmol/l)
Number of subjects: 19
Study 10430967 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis patients on a controlled low-nitrate diet (approximately 330 micromol/d) for 48 hours.
Number of subjects: 0
Study 10430967 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group).
Number of subjects: 0
Study 10430967 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis patients with elevated plasma levels of citrulline and asymmetric dimethylarginine (ADMA).
Number of subjects: 0
Study 10430967 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis patients receiving antihypertensive therapy.
Number of subjects: 0
Study 8699846 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 1,200 mg daily for 2 months
Number of subjects: 0
Study 8699846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2347957 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame (15 mg/kg body weight)
Number of subjects: 10
Study 2347957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2347957 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame
Number of subjects: 10
Study 379366 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy with tetracycline
Number of subjects: 50
Study 379366 — intervention group
Group type: COMPARATOR
Intervention: Chlamydia trachomatis infection
Number of subjects: 50
Study 379366 — intervention group
Group type: COMPARATOR
Intervention: Chlamydia trachomatis infection in female partners
Number of subjects: 50
Study 31699723 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified nutrition group (increased vegetable and fruit, reduced dairy milk)
Number of subjects: 81
Study 31699723 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified nutrition group (lycopene supplementation)
Number of subjects: 81
Study 31699723 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity group (brisk walking)
Number of subjects: 81
Study 31699723 — intervention group
Group type: COMPARATOR
Intervention: Control group (nutrition)
Number of subjects: 81
Study 31699723 — intervention group
Group type: COMPARATOR
Intervention: Control group (physical activity)
Number of subjects: 81
Study 28570250 — intervention group
Group type: EXPERIMENTAL
Intervention: NPWTi with 0.125% sodium hypochlorite solution
Number of subjects: 20
Study 28570250 — intervention group
Group type: COMPARATOR
Intervention: NPWT without instillation
Number of subjects: 20
Study 26267728 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate gel
Number of subjects: 0
Study 26267728 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient's Self-Assessment (PSA) scale
Number of subjects: 0
Study 23347472 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive inhibition assessed with the Color‐Word Interference Test (D‐KEFS)
Number of subjects: 36
Study 23347472 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate variability (HRV) measured using high frequency (HF) power (ms(2))
Number of subjects: 36
Study 23347472 — intervention group
Group type: COMPARATOR
Intervention: Control for depression
Number of subjects: 36
Study 21316788 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured behavioural intervention to increase physical activity
Number of subjects: 43
Study 21316788 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 43
Study 19746242 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 86
Study 19746242 — intervention group
Group type: COMPARATOR
Intervention: Nonspironolactone (Control)
Number of subjects: 86
Study 17825710 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-segment elevation criteria
Number of subjects: 116
Study 17825710 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-segment elevation and depression criteria
Number of subjects: 116
Study 15505095 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 186
Study 15505095 — intervention group
Group type: COMPARATOR
Intervention: Control group (ICD activated, CRT off)
Number of subjects: 186
Study 11488132 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with epinephrine 1:80,000
Number of subjects: 43
Study 11488132 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% mepivacaine with epinephrine 1:100,000
Number of subjects: 43
Study 11488132 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% mepivacaine with no associated vasoconstrictor
Number of subjects: 43
Study 10422491 — intervention group
Group type: EXPERIMENTAL
Intervention: pravastatin Lipostat 20
Number of subjects: 89
Study 10422491 — intervention group
Group type: EXPERIMENTAL
Intervention: phenofibrate Lipanthyl 200M
Number of subjects: 89
Study 10422491 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin Zocor 20
Number of subjects: 89
Study 10422491 — intervention group
Group type: EXPERIMENTAL
Intervention: no hypolipemic medication
Number of subjects: 89
Study 10422491 — intervention group
Group type: COMPARATOR
Intervention: Control group (no accelerated atherosclerosis)
Number of subjects: 89
Study 7999482 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous i.v. infusion (group A: 1.25 u.h‐1)
Number of subjects: 80
Study 7999482 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated i.v. boluses (10 u./2 h)
Number of subjects: 80
Study 2897785 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (SRIF) infusion (500 micrograms/h) for 90 min before and 5 h after a protein meal (240 g of meat)
Number of subjects: 11
Study 2897785 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 11
Study 30277030 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselor-initiated (CI) condition
Number of subjects: 248
Study 30277030 — intervention group
Group type: COMPARATOR
Intervention: Self-paced (SP) condition
Number of subjects: 248
Study 27121602 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind, placebo-controlled food challenge (DBPCFC)
Number of subjects: 1142
Study 27121602 — intervention group
Group type: COMPARATOR
Intervention: Placebo day during DBPCFC
Number of subjects: 1142
Study 27121602 — intervention group
Group type: EXPERIMENTAL
Intervention: DBPCFC with no severe immediate reactions
Number of subjects: 1142
Study 26258613 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate model compensation
Number of subjects: 202
Study 26258613 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate model
Number of subjects: 202
Study 23921906 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal immunochemical test (FIT) outreach
Number of subjects: 6970
Study 23921906 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy outreach
Number of subjects: 6970
Study 23921906 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 6970
Study 23921906 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between FIT and Colonoscopy outreach
Number of subjects: 6970
Study 21059836 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel (5 g/d)
Number of subjects: 112
Study 21059836 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel (10 g/d)
Number of subjects: 112
Study 21059836 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH (3 μg/kg/d)
Number of subjects: 112
Study 21059836 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH (5 μg/kg/d)
Number of subjects: 112
Study 21059836 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-treatment with rhGH
Number of subjects: 112
Study 21059836 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 112
Study 21059836 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in testosterone and insulin‐like growth factor 1 levels
Number of subjects: 112
Study 18505564 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (specific agents not mentioned)
Number of subjects: 0
Study 18505564 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 0
Study 18505564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16616744 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative measurement of IL‐6 by ELISA
Number of subjects: 50
Study 16616744 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative measurement of TNF‐alpha by ELISA
Number of subjects: 50
Study 16616744 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative measurement of IL‐8 by ELISA
Number of subjects: 50
Study 16616744 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative measurement of E‐selectin by ELISA
Number of subjects: 50
Study 14669258 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa oil (black seed oil) at a dose of 40 to 80 mg/kg/day
Number of subjects: 152
Study 14669258 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa oil (black seed oil)
Number of subjects: 152
Study 11307093 — intervention group
Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt (TIPS)
Number of subjects: 65
Study 11307093 — intervention group
Group type: COMPARATOR
Intervention: H-graft portacaval shunt
Number of subjects: 65
Study 9085939 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (severe acute myocardial infarction)
Number of subjects: 34
Study 9085939 — intervention group
Group type: COMPARATOR
Intervention: Nonsurvivors (n = 13)
Number of subjects: 34
Study 9085939 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma IL-1 receptor antagonist and IL-10 levels
Number of subjects: 34
Study 1493941 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF treatment
Number of subjects: 0
Study 1493941 — intervention group
Group type: COMPARATOR
Intervention: Control (no GM-CSF treatment)
Number of subjects: 0
Study 3159197 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 0
Study 3159197 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 0
Study 31943173 — intervention group
Group type: EXPERIMENTAL
Intervention: Book-based language intervention program
Number of subjects: 464
Study 31375443 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (LB)
Number of subjects: 231
Study 31375443 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 231
Study 27890522 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (alpha-adrenergic blocker)
Number of subjects: 0
Study 27890522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25539697 — intervention group
Group type: EXPERIMENTAL
Intervention: Deliberate practice (DP)
Number of subjects: 14
Study 25539697 — intervention group
Group type: COMPARATOR
Intervention: Control training (educational videos or journal articles)
Number of subjects: 14
Study 24187118 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visiting program (9 visits over 3 years)
Number of subjects: 302
Study 24187118 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no home visits)
Number of subjects: 302
Study 24187118 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visiting program
Number of subjects: 302
Study 21221815 — intervention group
Group type: EXPERIMENTAL
Intervention: Intergenerational volunteering intervention (hour-long volunteer sessions with kindergarten and older elementary classes over 5 months)
Number of subjects: 15
Study 21221815 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 15
Study 19028148 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 110
Study 19028148 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy (OC)
Number of subjects: 110
Study 17264337 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC 6) and Paclitaxel (200 mg/m2 every 3 weeks)
Number of subjects: 100
Study 17264337 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (1 g/m2 days 1 and 8) and Cisplatin (60 mg/m2 day 1 every 3 weeks)
Number of subjects: 100
Study 12933419 — intervention group
Group type: EXPERIMENTAL
Intervention: IT fentanyl 25 micro g and hyperbaric bupivacaine 2.5 mg (Group H)
Number of subjects: 37
Study 12933419 — intervention group
Group type: COMPARATOR
Intervention: IT fentanyl 25 micro g and plain bupivacaine 2.5 mg (Group P)
Number of subjects: 37
Study 10407502 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-apheresis and drugs
Number of subjects: 36
Study 10407502 — intervention group
Group type: COMPARATOR
Intervention: Drugs only (control group)
Number of subjects: 36
Study 8888091 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 110
Study 8888091 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium
Number of subjects: 110
Study 8888091 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium
Number of subjects: 110
Study 1810257 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (1000 mg orally)
Number of subjects: 0
Study 1810257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6630599 — intervention group
Group type: EXPERIMENTAL
Intervention: Curettage and electrodesiccation once
Number of subjects: 0
Study 6630599 — intervention group
Group type: EXPERIMENTAL
Intervention: Curettage and electrodesiccation three times
Number of subjects: 0
Study 3918495 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin V (pcV)
Number of subjects: 100
Study 3918495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 29024278 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor dapagliflozin
Number of subjects: 0
Study 29024278 — intervention group
Group type: COMPARATOR
Intervention: Loop diuretic bumetanide
Number of subjects: 0
Study 27729061 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Conversation Skills support plus vitamin D supplementation (1000 IU cholecalciferol)
Number of subjects: 600
Study 27729061 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Conversation Skills support plus placebo
Number of subjects: 600
Study 27729061 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus vitamin D supplementation (1000 IU cholecalciferol)
Number of subjects: 600
Study 27729061 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus placebo
Number of subjects: 600
Study 24473242 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-stroke care with exercise
Number of subjects: 20
Study 24473242 — intervention group
Group type: COMPARATOR
Intervention: Post-stroke care without exercise
Number of subjects: 20
Study 22458432 — intervention group
Group type: EXPERIMENTAL
Intervention: MVG technique
Number of subjects: 72
Study 22458432 — intervention group
Group type: COMPARATOR
Intervention: Anatomic CTI ablation (unmatched)
Number of subjects: 72
Study 22458432 — intervention group
Group type: COMPARATOR
Intervention: Anatomic CTI ablation (matched)
Number of subjects: 72
Study 20394544 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber tube
Number of subjects: 46
Study 20394544 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone tube
Number of subjects: 46
Study 20394544 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study 17967833 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 257
Study 15680453 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgery (haematoma evacuation within 24 hours of randomisation)
Number of subjects: 1033
Study 15680453 — intervention group
Group type: COMPARATOR
Intervention: Initial conservative treatment (medical treatment, with later evacuation allowed if necessary)
Number of subjects: 1033
Study 12922086 — intervention group
Group type: EXPERIMENTAL
Intervention: New pediatric tick-borne encephalitis (TBE) vaccine
Number of subjects: 3559
Study 10669065 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily combination tablet administration (8 mg buprenorphine + 2 mg naloxone)
Number of subjects: 26
Study 10669065 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg alternate-day buprenorphine administration
Number of subjects: 26
Study 10669065 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg alternate-day buprenorphine administration
Number of subjects: 26
Study 10669065 — intervention group
Group type: COMPARATOR
Intervention: Placebo on interposed day during alternate-day treatment
Number of subjects: 26
Study 8797613 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose anti-tumor necrosis factor therapy
Number of subjects: 553
Study 8797613 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-tumor necrosis factor therapy
Number of subjects: 553
Study 8797613 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose anti-tumor necrosis factor therapy
Number of subjects: 553
Study 1632683 — intervention group
Group type: EXPERIMENTAL
Intervention: Single donor-specific transfusion (DST) 24 to 48 hours before transplant with intravenous cyclosporine initiated after transfusion
Number of subjects: 86
Study 1632683 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple pretransplant DSTs with cyclosporine begun pretransplant
Number of subjects: 86
Study 1632683 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple pretransplant DSTs with cyclosporine begun after transplant
Number of subjects: 86
Study 6208968 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm formula based on cows' milk
Number of subjects: 61
Study 6208968 — intervention group
Group type: COMPARATOR
Intervention: Banked breast milk or maternal milk supplement
Number of subjects: 61
Study 31567665 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose-Derived Cellular Bone Matrix (ACBM)
Number of subjects: 140
Study 31567665 — intervention group
Group type: COMPARATOR
Intervention: Autologous Bone Graft (Autograft)
Number of subjects: 140
Study 29110305 — intervention group
Group type: EXPERIMENTAL
Intervention: Trees
Number of subjects: 50
Study 29110305 — intervention group
Group type: COMPARATOR
Intervention: Playground equipment and sitting/eating areas
Number of subjects: 50
Study 30641007 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinfeng Capsule (XFC), 0.5 g per pill, 3 pills each time, three times per day for 12 weeks
Number of subjects: 76
Study 30641007 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine (SASP), 0.25 g per tablet, 4 tablets each time, twice per day for 12 weeks
Number of subjects: 76
Study 24708675 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin trough level < 10 μg/mL
Number of subjects: 98
Study 24708675 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin trough level 10 μg/mL to < 15 μg/mL
Number of subjects: 98
Study 24708675 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin trough level ≥ 15 μg/mL
Number of subjects: 98
Study 24708675 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin trough level < 10 μg/mL (after excluding certain patients)
Number of subjects: 98
Study 24708675 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin trough level 10 μg/mL to < 15 μg/mL (after excluding certain patients)
Number of subjects: 98
Study 24708675 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin trough level ≥ 15 μg/mL (after excluding certain patients)
Number of subjects: 98
Study 22124360 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose group (3700 MBq)
Number of subjects: 341
Study 22124360 — intervention group
Group type: COMPARATOR
Intervention: Low-dose group (1110 MBq)
Number of subjects: 341
Study 20556834 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (1 mg/d)
Number of subjects: 74
Study 20556834 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 74
Study 18565433 — intervention group
Group type: EXPERIMENTAL
Intervention: Communities That Care (CTC) intervention
Number of subjects: 4407
Study 18565433 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4407
Study 15925951 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus exercise (DE) with IF obesity
Number of subjects: 209
Study 15925951 — intervention group
Group type: COMPARATOR
Intervention: Diet alone (DA) with IF obesity
Number of subjects: 209
Study 15925951 — intervention group
Group type: COMPARATOR
Intervention: Diet alone (DA) with ASF obesity
Number of subjects: 209
Study 15925951 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus exercise (DE) with ASF obesity
Number of subjects: 209
Study 11818342 — intervention group
Group type: EXPERIMENTAL
Intervention: Information presented in terms of all risk reductions (absolute, relative, number needed to treat)
Number of subjects: 1500
Study 11818342 — intervention group
Group type: EXPERIMENTAL
Intervention: Information presented only in terms of relative risk reduction
Number of subjects: 1500
Study 11818342 — intervention group
Group type: EXPERIMENTAL
Intervention: Information presented in terms of absolute risk reduction or number needed to treat
Number of subjects: 1500
Study 10609696 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 0
Study 10609696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8578357 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye patching (patched group)
Number of subjects: 33
Study 8578357 — intervention group
Group type: COMPARATOR
Intervention: No eye patching (nonpatched group)
Number of subjects: 33
Study 8578357 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (patched and nonpatched)
Number of subjects: 33
Study 2007923 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with reduced protein content (1.3 gm/dl)
Number of subjects: 20
Study 2007923 — intervention group
Group type: COMPARATOR
Intervention: Standard infant formula (protein 1.5 gm/dl)
Number of subjects: 20